Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

• Disease Name: Angiosarcoma
• MONDO ID: (if available)
• Category: Cancer

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Angiosarcoma. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

• What are the primary pathophysiological mechanisms?
• What molecular pathways are dysregulated?
• What cellular processes are affected?

2. Key Molecular Players

• Genes/Proteins: Which genes are causally involved or implicated?
• Chemical Entities: What metabolites, drugs, or small molecules are relevant?
• Cell Types: Which cell types are primarily affected?
• Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

• What biological processes (GO terms) are disrupted?
• Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

• Where in the cell do key processes occur?
• Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

• What is the sequence of events from initial trigger to clinical manifestation?
• Are there distinct stages or phases?

6. Phenotypic Manifestations

• What are the key clinical phenotypes?
• How do they relate to the underlying mechanisms?

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic claims
• Prioritize recent reviews and landmark papers
• Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Angiosarcoma Pathophysiology Research Report (Cancer)

Disease identifiers

• Disease name: Angiosarcoma
• MONDO ID: Not confirmed from the retrieved sources in this run (not reported in the cited texts).

1) Key concepts and definitions (current understanding)

Angiosarcoma is a rare, aggressive malignant neoplasm of endothelial lineage (blood and/or lymphatic endothelium) characterized by highly infiltrative growth, early hematogenous spread, and marked biologic heterogeneity across anatomic sites and etiologies (sporadic/primary vs secondary after radiation or chronic lymphedema). Molecularly, angiosarcoma is best conceptualized as a disease of dysregulated angiogenesis and endothelial signaling, with frequent activation of VEGF/VEGFR, Angiopoietin–Tie, and downstream MAPK and PI3K/AKT/mTOR axes, coupled to subtype-enriched oncogenic drivers (e.g., MYC amplification in secondary radiation/lymphedema-associated tumors; KDR and PIK3CA alterations in primary breast angiosarcoma; and UV-driven hypermutation in scalp/face cutaneous disease). (chen2020optimalclinicalmanagement pages 11-12, chen2020optimalclinicalmanagement pages 9-11, painter2020theangiosarcomaproject pages 4-7)

A concise mechanistic framing from a comprehensive molecular review is that angiosarcomas “often manifest through genetic mutations (KDR(VEGFR-2), PLCG1, PTPRB) … or amplification (FLT4(VEGFR-3))”, highlighting recurrent perturbations of endothelial receptor tyrosine kinase signaling and its proximal effectors. (chen2020optimalclinicalmanagement pages 5-7)

2) Core pathophysiology

2.1 Primary pathophysiological mechanisms

(A) Pathologic angiogenesis/lymphangiogenesis as a central program - VEGF signaling is prominent in angiosarcoma biology. Immunohistochemistry data compiled in the molecular review show high expression of VEGF pathway components (e.g., VEGF-A/VEGFRs) across cases, consistent with a phenotype dependent on endothelial growth factor signaling. (chen2020optimalclinicalmanagement pages 9-11) - The Angiopoietin–Tie axis contributes to vascular maturation/maintenance and appears biologically relevant in angiosarcoma; Tie/Ang proteins were detected in substantial fractions of cases by immunohistochemistry (e.g., Tie-2, Ang-1/2), and expression levels correlated with survival in at least one cohort. (chen2020optimalclinicalmanagement pages 11-12)

(B) Oncogenic rewiring downstream of endothelial receptors - Downstream signaling nodes repeatedly implicated include FAK, MAPK, and PI3K/AKT/mTOR, which couple extracellular pro-angiogenic signals to proliferation, survival, migration, and invasion. (chen2020optimalclinicalmanagement pages 11-12, kumari2023primarycardiacangiosarcoma pages 3-4)

(C) DNA damage/etiology-specific mutagenesis shapes subtype biology - Radiation-associated angiosarcoma (RT-AS) exhibits features of ionizing radiation damage and distinct genomic landscapes compared with sporadic angiosarcoma, with mutational patterns consistent with error-prone repair of DNA double-strand breaks (microhomology-mediated mechanisms and/or non-homologous end joining). (dermawan2023distinctgenomiclandscapes pages 8-10, dermawan2023distinctgenomiclandscapes pages 1-3) - UV-associated cutaneous angiosarcoma (scalp/face) displays a UV mutational signature and high tumor mutational burden (TMB), supporting a causative role for UV damage in a clinically important subset. (painter2020theangiosarcomaproject pages 4-7, painter2020theangiosarcomaproject pages 7-11)

2.2 Dysregulated molecular pathways

VEGF/VEGFR signaling (KDR/FLT4 and effectors) - Activating or recurrent alterations affecting VEGFR signaling include KDR (VEGFR2) mutations and FLT4 (VEGFR3) amplifications, with subtype-specific enrichment (e.g., KDR in primary breast; FLT4 often co-amplified with MYC in radiation-associated breast angiosarcoma). (chen2020optimalclinicalmanagement pages 9-11, chang2024clinicopathologicandmolecular pages 10-11)

Angiopoietin–Tie / vascular stability signaling (TIE2 pathway) - Loss-of-function PTPRB mutations are proposed to deregulate Tie-2 and VEGFR2 signaling (removing phosphatase “braking” on endothelial receptor pathways). (chen2020optimalclinicalmanagement pages 11-12)

MAPK pathway - PLCG1 activating mutations (e.g., R707Q) can increase IP3 generation and activate MAPK signaling, and PLCG1 mutations may be mutually exclusive with VEGFR2/KDR mutations in some series—supporting alternative, convergent mechanisms to activate downstream growth pathways. (chen2020optimalclinicalmanagement pages 11-12)

PI3K pathway - In primary breast angiosarcoma, activating PIK3CA mutations are strongly enriched and functionally activating, indicating PI3K pathway dependence in this subtype and a plausible vulnerability to PI3Kα inhibition. (painter2020theangiosarcomaproject pages 4-7)

MYC-driven transcriptional/angiogenic programs (secondary disease) - Secondary angiosarcomas (especially radiation- or lymphedema-associated cutaneous/breast/chest wall tumors) show frequent high-level MYC amplification and MYC-associated transcriptional changes (including miRNA programs) linked to a pro-angiogenic state. (chen2020optimalclinicalmanagement pages 9-11, chang2024clinicopathologicandmolecular pages 10-11)

3) Key molecular players

3.1 Genes/proteins (HGNC symbols)

Subtype-enriched genomic alterations with statistics

Primary breast angiosarcoma (sporadic) - KDR (VEGFR2): 8/12 (66.7%) in a 2024 breast angiosarcoma cohort, including hotspot p.T771 in multiple cases. (chang2024clinicopathologicandmolecular pages 10-11) - PIK3CA: 5/12 (41.7%) in the same cohort; Angiosarcoma Project WES found primary breast angiosarcoma significantly enriched for PIK3CA mutations (9/18 vs 1/29; p=0.0003). (chang2024clinicopathologicandmolecular pages 10-11, painter2020theangiosarcomaproject pages 4-7) - TP53: 3/12 (25%) in the same cohort. (chang2024clinicopathologicandmolecular pages 10-11) - Mechanistic interpretation: Angiosarcoma Project identified TP53 (25%; 9/36 patients) and KDR (22%; 8/36 patients) as significantly mutated above background and mutually exclusive (p=0.02); KDR alterations were concentrated in primary breast tumors. (painter2020theangiosarcomaproject pages 4-7)

Radiation-associated breast/chest wall angiosarcoma (secondary) - MYC amplification: 89/97 (91.8%) in a large 2024 breast radiation-associated series; in the neoadjuvant-treated subset, all 10 sequenced radiation-associated cases showed MYC amplification. (chang2024clinicopathologicandmolecular pages 10-11, chang2024clinicopathologicandmolecular pages 1-3) - FLT4 amplification: 10/74 (13.5%) in the same report, often co-amplified with MYC. (chang2024clinicopathologicandmolecular pages 10-11) - PTPRB: loss-of-function mutations reported in 10/39 secondary angiosarcomas in a prior mechanistic review. (chen2020optimalclinicalmanagement pages 11-12) - Distinct radiation-associated genomic landscape: radiation-associated angiosarcoma was reported enriched for MYC, FLT4, CRKL, HRAS, KMT2D compared with sporadic angiosarcoma, whereas sporadic tumors were enriched for TP53, KDR, ATM, ATRX. (dermawan2023distinctgenomiclandscapes pages 1-3)

UV-associated cutaneous angiosarcoma (head/neck/face/scalp; HNFS) - Angiosarcoma Project: HNFS tumors had much higher median TMB (20.7 muts/Mb vs 2.8 non-HNFS) and a dominant UV mutational signature in 10/12 HNFS samples. (painter2020theangiosarcomaproject pages 4-7) - Exceptional immunotherapy responses were linked to very high TMB and UV signature in individual HNFS cases treated with pembrolizumab (durable >2 years off therapy). (painter2020theangiosarcomaproject pages 7-11) - Spatial multi-omic profiling of Asian head/neck angiosarcoma reported recurrent mutations in CSMD3 (18%), LRP1B (18%), MUC16 (18%), POT1 (16%), TP53 (16%), and higher TMB in UV-positive disease (p=0.0294). (loh2023spatialtranscriptomicsreveal pages 1-2)

Other recurrent/functional drivers (across angiosarcoma) - PLCG1 (e.g., R707Q): reported recurrently (e.g., 3/34 in one cohort; also present in larger series), functionally de-repressing PLCγ1 and activating MAPK signaling; may confer resistance to therapies targeting VEGF/KDR in some contexts. (chen2020optimalclinicalmanagement pages 11-12, kumari2023primarycardiacangiosarcoma pages 3-4) - TP53: variable alteration rates across series; functional role supported by animal/endothelial models where TP53 alterations can lead to angiosarcoma-like tumors. (chen2020optimalclinicalmanagement pages 9-11, chen2020optimalclinicalmanagement pages 7-8)

3.2 Chemical entities (therapeutically relevant; CHEBI)

Angiosarcoma treatments are not purely “pathophysiology,” but many clinical implementations directly target core dysregulated pathways: - Anti-angiogenic / VEGF-axis agents: bevacizumab, sorafenib, pazopanib, regorafenib (and others) are used clinically; reported activity is modest in unselected disease (e.g., bevacizumab ORR 9% (2/23); sorafenib ORR 15–23% with median PFS ~3 months; pazopanib ORR ~20% in retrospective data). (chen2020optimalclinicalmanagement pages 5-7) - Immune checkpoint inhibitors (ICIs): pembrolizumab and other anti–PD-1/PD-L1 regimens show notable activity in select cutaneous/UV-high disease and variable responses otherwise. (painter2020theangiosarcomaproject pages 7-11, chen2020optimalclinicalmanagement pages 5-7)

3.3 Cell types (CL) and anatomical locations (UBERON)

Key cell types involved - Endothelial tumor cells (blood and/or lymphatic endothelium) are the malignant compartment. (chen2020optimalclinicalmanagement pages 11-12, kumari2023primarycardiacangiosarcoma pages 3-4) - Immune microenvironment cell types repeatedly implicated include CD8+ T cells, macrophages (CD68+), neutrophils (CD15+), and FOXP3+ regulatory T cells, varying by immune-hot vs immune-cold spatial phenotypes. (loh2023spatialtranscriptomicsreveal pages 1-2)

Common anatomical sites / subtype anchors - Cutaneous/subcutaneous disease dominates population incidence datasets (majority of cases). (wagner2024incidenceandpresenting pages 1-2) - Scalp/face (UV-exposed head/neck) are key for the UV/TMB-high subtype. (painter2020theangiosarcomaproject pages 4-7, painter2020theangiosarcomaproject pages 7-11) - Breast/chest wall are key for radiation-associated secondary angiosarcoma after breast irradiation. (wagner2024incidenceandpresenting pages 1-2, chang2024clinicopathologicandmolecular pages 10-11)

4) Biological processes (GO-oriented pathophysiology mapping)

The evidence supports disruption of the following GO-relevant process classes: - Angiogenesis / vasculature development (VEGF/VEGFR, Ang/Tie). (chen2020optimalclinicalmanagement pages 11-12, chen2020optimalclinicalmanagement pages 9-11) - Endothelial cell proliferation, migration, and sprouting driven by VEGF receptor activation and downstream PI3K/MAPK cascades. (kumari2023primarycardiacangiosarcoma pages 3-4) - Response to hypoxia (e.g., endoglin upregulation under hypoxia; pro-angiogenic remodeling). (chen2020optimalclinicalmanagement pages 5-7) - DNA damage response / double-strand break repair and mutational processes specific to radiation-associated tumors. (dermawan2023distinctgenomiclandscapes pages 8-10, dermawan2023distinctgenomiclandscapes pages 1-3) - Response to ultraviolet light / UV-induced mutagenesis in HNFS tumors. (painter2020theangiosarcomaproject pages 4-7, painter2020theangiosarcomaproject pages 7-11) - Immune response / tumor inflammation programs (immune-hot vs cold; tumor inflammation signature differences). (loh2023spatialtranscriptomicsreveal pages 1-2)

5) Cellular components (where key processes occur)

Mechanistic events described in the evidence primarily map to: - Plasma membrane receptor complexes (VEGFR2/KDR, VEGFR3/FLT4, Tie receptors) initiating signaling. (kumari2023primarycardiacangiosarcoma pages 3-4, chen2020optimalclinicalmanagement pages 5-7) - Cytosolic signaling complexes (PLCγ1-mediated phosphoinositide signaling, MAPK and PI3K/AKT/mTOR cascades). (chen2020optimalclinicalmanagement pages 11-12, kumari2023primarycardiacangiosarcoma pages 3-4) - Nuclear transcriptional programs (MYC-driven transcription and miRNA programs). (chen2020optimalclinicalmanagement pages 9-11, chang2024clinicopathologicandmolecular pages 10-11) - Tumor microenvironment compartments with spatially organized immune infiltration/exclusion patterns. (loh2023spatialtranscriptomicsreveal pages 1-2)

6) Disease progression model (sequence of events)

6.1 Etiology-dependent initiation → transformation

1. Initiating insult or predisposition
2. UV exposure for HNFS cutaneous angiosarcoma, associated with UV mutational signatures and high TMB. (painter2020theangiosarcomaproject pages 4-7, painter2020theangiosarcomaproject pages 7-11)
3. Ionizing radiation for secondary breast/chest wall angiosarcoma, with latency on the order of years and distinct genomic landscapes consistent with radiation-induced DNA damage and repair. (dermawan2023distinctgenomiclandscapes pages 1-3, wagner2024incidenceandpresenting pages 1-2)

4. Chronic lymphedema and other secondary contexts are recognized risk settings and molecularly associated with MYC amplification in secondary disease. (wagner2024incidenceandpresenting pages 1-2, chen2020optimalclinicalmanagement pages 9-11)

5. Early molecular driver acquisition and lineage program

6. Secondary radiation/lymphedema-associated lesions frequently acquire MYC amplification, driving a pro-angiogenic transcriptional program (including miRNA changes and reduced anti-angiogenic factors). (chen2020optimalclinicalmanagement pages 9-11, chang2024clinicopathologicandmolecular pages 10-11)

7. Primary breast tumors show KDR and PIK3CA activation, linking endothelial growth factor sensing directly to proliferative survival signaling (PI3K pathway). (painter2020theangiosarcomaproject pages 4-7, chang2024clinicopathologicandmolecular pages 10-11)

8. Progression: signaling convergence, invasion, and metastasis

9. Across subtypes, signaling converges on MAPK and PI3K/AKT/mTOR to support proliferation/survival and the invasive vascular phenotype. (chen2020optimalclinicalmanagement pages 11-12, kumari2023primarycardiacangiosarcoma pages 3-4)
10. Radiation-associated tumors may acquire additional co-alterations (e.g., FLT4, HRAS, KMT2D) consistent with progression and genomic instability. (dermawan2023distinctgenomiclandscapes pages 1-3, chang2024clinicopathologicandmolecular pages 10-11)

6.2 Distinct “immune phenotypes” influence clinical behavior and treatment sensitivity

• UV/TMB-high HNFS tumors can be particularly immunogenic, and exceptional responses to PD-1 blockade have been observed in that context, supporting immune selection/escape as part of progression. (painter2020theangiosarcomaproject pages 7-11)
• Spatial profiling reveals immune-hot cases may exhibit tumor-excluded inflammation (immune cells present but spatially segregated), potentially contributing to variable responses. (loh2023spatialtranscriptomicsreveal pages 1-2)

7) Phenotypic manifestations (HP-oriented)

Although detailed HP-term enumerations were not provided explicitly in the retrieved texts, the evidence supports the following phenotype classes: - Aggressive local infiltration and high recurrence risk, particularly in cutaneous and radiation-associated breast/chest wall disease. (wagner2024incidenceandpresenting pages 1-2, chen2020optimalclinicalmanagement pages 5-7) - Early metastasis with poor prognosis overall; cutaneous angiosarcoma review reports mean 5-year survival ~33.5%. (guan2023cutaneousangiosarcomaa pages 1-2) - Site-specific presentations: UV-exposed scalp/face lesions (often misrecognized early) and post-radiation chest wall/breast cutaneous nodules in the irradiated field. (wagner2024incidenceandpresenting pages 1-2, dermawan2023distinctgenomiclandscapes pages 1-3)

8) Recent developments and latest research (prioritizing 2023–2024)

8.1 Population-level epidemiology (2024)

A US population-based analysis (USCS NPCR–SEER combined) identified 19,289 cases (2001–2020) and reported that “angiosarcoma incidence doubled from 657 cases in 2001 to 1312 in 2019”, with increasing incidence particularly driven by secondary breast/chest-wall disease in women. (JAMA Network Open, 2024-04; https://doi.org/10.1001/jamanetworkopen.2024.6235) (wagner2024incidenceandpresenting pages 1-2)

8.2 High-resolution subtype genomics and precision targets (2023–2024)

• Radiation-associated angiosarcoma shows a distinct landscape compared with other radiation-associated sarcomas and compared with sporadic angiosarcoma, with enrichment for MYC/FLT4/HRAS/KMT2D and relative depletion of TP53 alterations in the radiation-associated setting. (The Journal of Pathology, 2023-06; https://doi.org/10.1002/path.6137) (dermawan2023distinctgenomiclandscapes pages 1-3)
• Breast angiosarcoma (2024): a large molecular cohort quantified near-ubiquitous MYC amplification in radiation-associated breast angiosarcoma (91.8%) and high prevalence of KDR and PIK3CA alterations in primary breast disease, strengthening the biologic separation of these entities and supporting subtype-tailored therapeutic hypotheses. (Genes Chromosomes Cancer, 2024-05; https://doi.org/10.1002/gcc.23240) (chang2024clinicopathologicandmolecular pages 10-11)
• Spatial transcriptomics in head/neck angiosarcoma (2023): defines immune-hot/intermediate/cold clusters and shows higher TMB in UV-positive cases, providing a framework for immunotherapy stratification beyond histology alone. (Communications Biology, 2023-04; https://doi.org/10.1038/s42003-023-04856-5) (loh2023spatialtranscriptomicsreveal pages 1-2)

8.3 Immunotherapy biomarker synthesis (2023)

A 2023 review of checkpoint inhibitors in cutaneous angiosarcoma collates evidence that cAS can display TMB-H, PD-L1 positivity, UV mutational signature, tertiary lymphoid structures, and abundant CD8+ TILs, providing mechanistic rationale for immunotherapy in selected patients. (Frontiers in Medicine, 2023-03; https://doi.org/10.3389/fmed.2023.1090168) (guan2023cutaneousangiosarcomaa pages 1-2)

9) Current applications and real-world implementations

9.1 Diagnostic and subclassification biomarkers

• MYC amplification testing (FISH) and/or MYC IHC is widely used to support diagnosis of secondary radiation- or lymphedema-associated angiosarcoma and to distinguish from benign/atypical post-radiation vascular lesions, consistent with the strong enrichment of MYC amplification in radiation-associated breast disease. (chen2020optimalclinicalmanagement pages 9-11, chang2024clinicopathologicandmolecular pages 10-11)
• Molecular subclassification has direct clinical implications: primary breast angiosarcoma (KDR/PIK3CA-driven) differs biologically and therapeutically from radiation-associated breast angiosarcoma (MYC-amplified). (painter2020theangiosarcomaproject pages 4-7, chang2024clinicopathologicandmolecular pages 10-11)

9.2 Therapeutic implementations linked to pathophysiology

• VEGF/angiogenesis pathway targeting is a rational strategy but shows heterogeneous and often modest efficacy in unselected populations (e.g., bevacizumab ORR 9%; sorafenib ORR 15–23%; pazopanib ORR ~20% in retrospective series), implying that pathway activation alone is insufficient as a biomarker and that subtype/driver selection is important. (chen2020optimalclinicalmanagement pages 5-7)
• Immune checkpoint blockade appears most compelling in UV/TMB-high cutaneous HNFS angiosarcoma, where durable, exceptional responses have been documented, consistent with the UV-driven hypermutated state and increased neoantigen burden. (painter2020theangiosarcomaproject pages 7-11)

10) Expert opinions and analysis (authoritative sources)

• The angiosarcoma field increasingly treats the disease as a set of molecularly distinct entities rather than one tumor type, supported by population-level subtype shifts (secondary breast/chest wall) and by strong subtype-enrichment of drivers such as MYC (secondary) vs KDR/PIK3CA (primary breast) vs UV/TMB-high HNFS disease. (wagner2024incidenceandpresenting pages 1-2, painter2020theangiosarcomaproject pages 4-7, chang2024clinicopathologicandmolecular pages 10-11)
• Mechanistic reviews emphasize angiogenesis signaling (VEGF/VEGFR, Tie/Ang) as central but also highlight why anti-angiogenic monotherapy is often insufficient: convergent downstream signaling (MAPK/PI3K), pathway redundancy, and genetically distinct etiologic subtypes. (chen2020optimalclinicalmanagement pages 11-12, chen2020optimalclinicalmanagement pages 5-7)

11) Relevant statistics and data (recent studies)

Epidemiology and incidence

• US (2001–2020): 19,289 cases; incidence doubled from 657 (2001) to 1312 (2019); adjusted annual increase leading to ~3.3 per 1,000,000 person-years (peak stated in the study excerpt), and most tumors were cutaneous/subcutaneous/breast (72.3%). (wagner2024incidenceandpresenting pages 1-2)

Genomics and biomarkers (selected quantitative findings)

• Radiation-associated breast angiosarcoma: MYC amplification 89/97 (91.8%); FLT4 amplification 10/74 (13.5%). (chang2024clinicopathologicandmolecular pages 10-11)
• Primary breast angiosarcoma: KDR 8/12 (66.7%), PIK3CA 5/12 (41.7%), TP53 3/12 (25%). (chang2024clinicopathologicandmolecular pages 10-11)
• Angiosarcoma Project WES: TP53 25% (9/36), KDR 22% (8/36), mutually exclusive (p=0.02); HNFS median TMB 20.7 muts/Mb vs 2.8 non-HNFS; UV signature in 10/12 HNFS. (painter2020theangiosarcomaproject pages 4-7)
• Cutaneous head/neck angiosarcoma immune biomarker compilation: PD-L1 positivity 33% (head/neck cAS in cited cohort) and UV signature 9/18 in one head/neck series. (guan2023cutaneousangiosarcomaa pages 1-2)

12) Knowledge base–ready annotation blocks

12.1 Pathophysiology description (narrative)

Angiosarcoma is an endothelial malignancy in which dysregulated angiogenesis/lymphangiogenesis is central. Key oncogenic events frequently occur at the level of endothelial receptor signaling (KDR/VEGFR2, FLT4/VEGFR3, Tie/Ang pathways) or in proximal effectors (PLCG1, PTPRB), converging on MAPK and PI3K/AKT/mTOR. Etiology strongly shapes pathophysiology: UV-driven HNFS tumors show UV mutational signatures and high TMB with immune responsiveness in select cases; radiation-associated breast/chest wall tumors show MYC amplification (often with FLT4 co-amplification) and radiation-associated mutational processes; and primary breast tumors are enriched for KDR and activating PIK3CA mutations. (chen2020optimalclinicalmanagement pages 5-7, painter2020theangiosarcomaproject pages 4-7, chang2024clinicopathologicandmolecular pages 10-11)

12.2 Gene/protein annotations (HGNC + mechanism + evidence)

• MYC (HGNC:7553) — amplification/overexpression in secondary (radiation-associated) angiosarcoma; linked to pro-angiogenic transcriptional and miRNA programs; near-ubiquitous in radiation-associated breast angiosarcoma cohorts. (chen2020optimalclinicalmanagement pages 9-11, chang2024clinicopathologicandmolecular pages 10-11)
• KDR (HGNC:6307; VEGFR2) — recurrent mutations enriched in primary breast angiosarcoma; significant driver in Angiosarcoma Project; activates angiogenic RTK signaling leading to PI3K/MAPK activation. (painter2020theangiosarcomaproject pages 4-7, chang2024clinicopathologicandmolecular pages 10-11, kumari2023primarycardiacangiosarcoma pages 3-4)
• PIK3CA (HGNC:8975) — activating mutations enriched in primary breast angiosarcoma and functionally activating; implies PI3K pathway dependence. (painter2020theangiosarcomaproject pages 4-7, chang2024clinicopathologicandmolecular pages 10-11)
• FLT4 (HGNC:3767; VEGFR3) — amplification in radiation-associated breast angiosarcoma (subset; often co-amplified with MYC), and in radiation-associated angiosarcoma more broadly. (chang2024clinicopathologicandmolecular pages 10-11, dermawan2023distinctgenomiclandscapes pages 1-3)
• PTPRB (HGNC:9668) — loss-of-function mutations in secondary angiosarcoma; proposed to deregulate Tie2/VEGFR2 signaling. (chen2020optimalclinicalmanagement pages 11-12)
• PLCG1 (HGNC:9065) — activating mutations (e.g., R707Q) increase phosphoinositide signaling and MAPK activation; may be mutually exclusive with KDR mutations in some cohorts. (chen2020optimalclinicalmanagement pages 11-12)
• TP53 (HGNC:11998) — recurrent driver, variable frequency by subtype; significant in Angiosarcoma Project and supported by animal models. (painter2020theangiosarcomaproject pages 4-7, chen2020optimalclinicalmanagement pages 7-8)

12.3 Cell-type involvement (CL)

• Endothelial cell (blood/lymphatic): malignant compartment; angiogenic signaling dependence. (kumari2023primarycardiacangiosarcoma pages 3-4, chen2020optimalclinicalmanagement pages 5-7)
• CD8+ T cell, macrophage, neutrophil, Treg (FOXP3+): immune microenvironment components with spatially organized “immune-hot/cold” patterns in head/neck disease. (loh2023spatialtranscriptomicsreveal pages 1-2)

12.4 Anatomical locations (UBERON)

• Skin of scalp/face/head & neck: enriched for UV signature/high TMB subtype. (painter2020theangiosarcomaproject pages 4-7, painter2020theangiosarcomaproject pages 7-11)
• Breast/chest wall (irradiated field): enriched for radiation-associated MYC-amplified subtype. (wagner2024incidenceandpresenting pages 1-2, chang2024clinicopathologicandmolecular pages 10-11)

12.5 Chemical entities (CHEBI; examples linked to mechanisms)

• Bevacizumab (anti-VEGF-A), pazopanib/sorafenib/regorafenib (multi-kinase VEGFR inhibitors) as real-world angiogenesis-directed agents with modest response rates in unselected populations. (chen2020optimalclinicalmanagement pages 5-7)
• Pembrolizumab (anti–PD-1) as an immunotherapy option with strongest mechanistic support in UV/TMB-high cutaneous HNFS disease. (painter2020theangiosarcomaproject pages 7-11, guan2023cutaneousangiosarcomaa pages 1-2)

13) Summary table (mechanisms, subtype biology, and immune features)

Table: This table summarizes angiosarcoma pathophysiology by major etiologic and clinical subtypes, highlighting subtype-enriched genomic alterations, pathway dysregulation, immune features, and clinical correlates. It is useful for linking disease mechanisms to diagnostic stratification and therapeutic hypotheses.

14) Evidence items (PMID-first, if available)

The retrieved full-text snippets frequently provided DOI/Journal/Year but did not reliably include PMIDs in the tool outputs for all sources. Key evidence items (with DOI and date): - Wagner MJ et al. JAMA Network Open 2024-04. “Incidence…US, 2001–2020.” https://doi.org/10.1001/jamanetworkopen.2024.6235 (wagner2024incidenceandpresenting pages 1-2) - Chang H-Y et al. Genes Chromosomes Cancer 2024-05. Breast angiosarcoma subtype genomics (MYC in radiation-associated; KDR/PIK3CA in primary). https://doi.org/10.1002/gcc.23240 (chang2024clinicopathologicandmolecular pages 10-11) - Loh JW et al. Communications Biology 2023-04. Spatial transcriptomics/immune landscapes in head & neck angiosarcoma. https://doi.org/10.1038/s42003-023-04856-5 (loh2023spatialtranscriptomicsreveal pages 1-2) - Dermawan JK et al. The Journal of Pathology 2023-06. Radiation-associated angiosarcoma genomic landscape. https://doi.org/10.1002/path.6137 (dermawan2023distinctgenomiclandscapes pages 1-3) - Guan L et al. Frontiers in Medicine 2023-03. Checkpoint inhibitor evidence in cutaneous angiosarcoma. https://doi.org/10.3389/fmed.2023.1090168 (guan2023cutaneousangiosarcomaa pages 1-2) - Chen TWW et al. Cancers 2020-11. Molecular biology and clinical management (VEGF/Tie, PTPRB/PLCG1, therapy response statistics). https://doi.org/10.3390/cancers12113321 (chen2020optimalclinicalmanagement pages 5-7) - Painter CA et al. Nature Medicine 2020-02. Angiosarcoma Project WES, UV/TMB findings, KDR/TP53/PIK3CA. https://doi.org/10.1038/s41591-019-0749-z (painter2020theangiosarcomaproject pages 4-7)

References

1. (chen2020optimalclinicalmanagement pages 11-12): Tom Wei-Wu Chen, Jessica Burns, Robin L. Jones, and Paul H. Huang. Optimal clinical management and the molecular biology of angiosarcomas. Cancers, 12:3321, Nov 2020. URL: https://doi.org/10.3390/cancers12113321, doi:10.3390/cancers12113321. This article has 27 citations.

2. (chen2020optimalclinicalmanagement pages 9-11): Tom Wei-Wu Chen, Jessica Burns, Robin L. Jones, and Paul H. Huang. Optimal clinical management and the molecular biology of angiosarcomas. Cancers, 12:3321, Nov 2020. URL: https://doi.org/10.3390/cancers12113321, doi:10.3390/cancers12113321. This article has 27 citations.

3. (painter2020theangiosarcomaproject pages 4-7): Corrie A. Painter, Esha Jain, Brett N. Tomson, Michael Dunphy, Rachel E. Stoddard, Beena S. Thomas, Alyssa L. Damon, Shahrayz Shah, Dewey Kim, Jorge Gómez Tejeda Zañudo, Jason L. Hornick, Yen-Lin Chen, Priscilla Merriam, Chandrajit P. Raut, George D. Demetri, Brian A. Van Tine, Eric S. Lander, Todd R. Golub, and Nikhil Wagle. The angiosarcoma project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Feb 2020. URL: https://doi.org/10.1038/s41591-019-0749-z, doi:10.1038/s41591-019-0749-z. This article has 291 citations and is from a highest quality peer-reviewed journal.

4. (chen2020optimalclinicalmanagement pages 5-7): Tom Wei-Wu Chen, Jessica Burns, Robin L. Jones, and Paul H. Huang. Optimal clinical management and the molecular biology of angiosarcomas. Cancers, 12:3321, Nov 2020. URL: https://doi.org/10.3390/cancers12113321, doi:10.3390/cancers12113321. This article has 27 citations.

5. (kumari2023primarycardiacangiosarcoma pages 3-4): Naina Kumari, Sagar Bhandari, Anzal Ishfaq, Samia Rauf R Butt, Chukwuyem Ekhator, Amanda Karski, Bijan Kadel, Mohamedalamin Alnoor Altayb Ismail, Tenzin N Sherpa, Ahmed Al Khalifa, Bashar Khalifah, Nhan Nguyen, Slobodan Lazarevic, Mohammad Uzair Zaman, Ashraf Ullah, and Vikas Yadav. Primary cardiac angiosarcoma: a review. Cureus, Jul 2023. URL: https://doi.org/10.7759/cureus.41947, doi:10.7759/cureus.41947. This article has 47 citations.

6. (dermawan2023distinctgenomiclandscapes pages 8-10): Josephine K Dermawan, Ping Chi, William D Tap, Evan Rosenbaum, Sandra D'Angelo, Kaled M Alektiar, and Cristina R Antonescu. Distinct genomic landscapes in radiation‐associated angiosarcoma compared with other radiation‐associated sarcoma histologies. The Journal of Pathology, 260:465-477, Jun 2023. URL: https://doi.org/10.1002/path.6137, doi:10.1002/path.6137. This article has 17 citations.

7. (dermawan2023distinctgenomiclandscapes pages 1-3): Josephine K Dermawan, Ping Chi, William D Tap, Evan Rosenbaum, Sandra D'Angelo, Kaled M Alektiar, and Cristina R Antonescu. Distinct genomic landscapes in radiation‐associated angiosarcoma compared with other radiation‐associated sarcoma histologies. The Journal of Pathology, 260:465-477, Jun 2023. URL: https://doi.org/10.1002/path.6137, doi:10.1002/path.6137. This article has 17 citations.

8. (painter2020theangiosarcomaproject pages 7-11): Corrie A. Painter, Esha Jain, Brett N. Tomson, Michael Dunphy, Rachel E. Stoddard, Beena S. Thomas, Alyssa L. Damon, Shahrayz Shah, Dewey Kim, Jorge Gómez Tejeda Zañudo, Jason L. Hornick, Yen-Lin Chen, Priscilla Merriam, Chandrajit P. Raut, George D. Demetri, Brian A. Van Tine, Eric S. Lander, Todd R. Golub, and Nikhil Wagle. The angiosarcoma project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Feb 2020. URL: https://doi.org/10.1038/s41591-019-0749-z, doi:10.1038/s41591-019-0749-z. This article has 291 citations and is from a highest quality peer-reviewed journal.

9. (chang2024clinicopathologicandmolecular pages 10-11): Hsin‐Yi Chang, Josephine K. Dermawan, Maria Gabriela Kuba, Aimee M. Crago, Samuel Singer, William Tap, Ping Chi, Sandra D'Angelo, Evan Rosenbaum, and Cristina R. Antonescu. Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma. Genes, May 2024. URL: https://doi.org/10.1002/gcc.23240, doi:10.1002/gcc.23240. This article has 6 citations.

10. (chang2024clinicopathologicandmolecular pages 1-3): Hsin‐Yi Chang, Josephine K. Dermawan, Maria Gabriela Kuba, Aimee M. Crago, Samuel Singer, William Tap, Ping Chi, Sandra D'Angelo, Evan Rosenbaum, and Cristina R. Antonescu. Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma. Genes, May 2024. URL: https://doi.org/10.1002/gcc.23240, doi:10.1002/gcc.23240. This article has 6 citations.

11. (loh2023spatialtranscriptomicsreveal pages 1-2): Jui Wan Loh, Jing Yi Lee, Abner Herbert Lim, Peiyong Guan, Boon Yee Lim, Bavani Kannan, Elizabeth Chun Yong Lee, Ning Xin Gu, Tun Kiat Ko, Cedric Chuan-Young Ng, Jeffrey Chun Tatt Lim, Joe Yeong, Jing Quan Lim, Choon Kiat Ong, Bin Tean Teh, and Jason Yongsheng Chan. Spatial transcriptomics reveal topological immune landscapes of asian head and neck angiosarcoma. Communications Biology, Apr 2023. URL: https://doi.org/10.1038/s42003-023-04856-5, doi:10.1038/s42003-023-04856-5. This article has 27 citations and is from a peer-reviewed journal.

12. (chen2020optimalclinicalmanagement pages 7-8): Tom Wei-Wu Chen, Jessica Burns, Robin L. Jones, and Paul H. Huang. Optimal clinical management and the molecular biology of angiosarcomas. Cancers, 12:3321, Nov 2020. URL: https://doi.org/10.3390/cancers12113321, doi:10.3390/cancers12113321. This article has 27 citations.

13. (wagner2024incidenceandpresenting pages 1-2): Michael J. Wagner, Vinod Ravi, Stephanie K. Schaub, Ed Y. Kim, Jeremy Sharib, Harveshp Mogal, Min Park, Michaela Tsai, Daniela Duarte-Bateman, Anthony Tufaro, Elizabeth T. Loggers, Lee D. Cranmer, Bonny Chau, Michael J. Hassett, Juneko Grilley-Olson, and Kelly G. Paulson. Incidence and presenting characteristics of angiosarcoma in the us, 2001-2020. JAMA Network Open, 7:e246235, Apr 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.6235, doi:10.1001/jamanetworkopen.2024.6235. This article has 38 citations and is from a peer-reviewed journal.

14. (guan2023cutaneousangiosarcomaa pages 1-2): Lucy Guan, Marisa Palmeri, and Roman Groisberg. Cutaneous angiosarcoma: a review of current evidence for treatment with checkpoint inhibitors. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1090168, doi:10.3389/fmed.2023.1090168. This article has 28 citations.

15. (chang2024clinicopathologicandmolecular pages 5-6): Hsin‐Yi Chang, Josephine K. Dermawan, Maria Gabriela Kuba, Aimee M. Crago, Samuel Singer, William Tap, Ping Chi, Sandra D'Angelo, Evan Rosenbaum, and Cristina R. Antonescu. Clinicopathologic and molecular correlates to neoadjuvant chemotherapy‐induced pathologic response in breast angiosarcoma. Genes, May 2024. URL: https://doi.org/10.1002/gcc.23240, doi:10.1002/gcc.23240. This article has 6 citations.

16. (chahardehi2024micrornasandangiosarcoma pages 3-4): Amir Modarresi Chahardehi, Arya Afrooghe, Nikoo Emtiazi, Sajjad Rafiei, Negin Jafarkhanloo Rezaei, Sarvin Dahmardeh, Fatemeh Farz, Zahra Naderi, Reza Arefnezhad, and Hossein Motedayyen. Micrornas and angiosarcoma: are there promising reports? Frontiers in Oncology, May 2024. URL: https://doi.org/10.3389/fonc.2024.1385632, doi:10.3389/fonc.2024.1385632. This article has 5 citations.

1. Disease Information

Overview

Angiosarcoma is a malignant mesenchymal neoplasm of endothelial cell origin that phenotypically and functionally recapitulates normal endothelium (PMID: 38391320). It is classified among soft tissue sarcomas and represents one of the most aggressive tumor types in this category, characterized by rapid local invasion, high rates of recurrence and metastasis, and poor overall prognosis. The tumor can arise virtually anywhere in the body, with the most common sites being skin (particularly the head and neck region in elderly patients), breast (both primary and radiation-associated), liver, heart, and spleen.

Key Identifiers

Synonyms and Alternative Names

• Hemangiosarcoma
• Malignant hemangioendothelioma
• Malignant angioendothelioma
• Lymphangiosarcoma (when arising from lymphatic endothelium)
• Stewart-Treves syndrome (when arising in the setting of chronic lymphedema post-mastectomy)

Information Sources

The information in this report is derived from aggregated disease-level resources including the SEER database, published case series, prospective clinical trials, genomic profiling studies, and systematic reviews. Individual patient-level data are referenced where available from clinical trials and case reports.

2. Etiology

Disease Causal Factors

Angiosarcoma arises through multiple distinct etiological pathways:

Sporadic/Primary: The majority of angiosarcomas arise spontaneously without identifiable environmental exposure. These tumors are driven by somatic mutations in angiogenic signaling pathways, particularly KDR (VEGFR2) mutations found in 70% of primary mammary angiosarcomas, PIK3CA/PIK3R1 mutations (70%), and PTPRB mutations (30%) (PMID: 32123305). The KDR p.T771R hotspot mutation was identified in 6 of 10 tumors with evidence suggestive of biallelism, indicating strong selection for enhanced VEGFR2 signaling.

Radiation-Associated: Secondary angiosarcomas arise in previously irradiated fields, most commonly after breast-conserving therapy for breast carcinoma. The median latency from index radiotherapy is 9.1 years (range 3.7–46.3 years) (PMID: 38791996). These tumors are molecularly defined by near-universal MYC amplification (100% of cases) and frequent FLT4 coamplification (25%) (PMID: 20949568). The incidence of secondary breast angiosarcoma increased 3-fold from approximately 10 to 30 cases per 100,000 person-years between 1992 and 2016 (P = 0.0037) (PMID: 37725702).

Chemically-Induced: Hepatic angiosarcoma has well-established associations with environmental carcinogens. A landmark US survey (1964–1974) identified 168 cases of hepatic angiosarcoma, of which 25% were associated with known etiologic factors including vinyl chloride monomer exposure, thorotrast (thorium dioxide) use in angiography, inorganic arsenic exposure, and androgenic-anabolic steroid treatment (PMID: 7199426). Vinyl chloride exposure was first recognized as a cause of hepatic angiosarcoma in the mid-1970s among polymerization workers (PMID: 945708). More recently, aristolochic acid exposure has been implicated in Asian liver angiosarcoma cohorts, with 80% (8/10) of liver angiosarcoma cases displaying a significant SBS22 mutation signature (PMID: 41394772).

UV-Associated: Head and neck angiosarcomas in sun-exposed skin carry UV mutational signatures (SBS7), with UV-positive cases harboring significantly higher tumor mutational burden than UV-negative cases (P = 0.0294) (PMID: 37106027).

Chronic Lymphedema-Associated (Stewart-Treves Syndrome): Angiosarcoma arising in the setting of chronic lymphedema following mastectomy and axillary lymph node dissection, first described by Stewart and Treves in 1948 (PMID: 26617830).

Risk Factors

Genetic Risk Factors

• TP53 germline variants (Li-Fraumeni syndrome): Germline TP53 pathogenic variants predispose to angiosarcoma, particularly in the context of prior radiotherapy. A novel germline TP53 variant (c.788del) was identified in a patient who developed radiation-associated angiosarcoma (PMID: 39734593). A novel germline risk allele in CHEK2 (p.P35L) was also identified in a Li-Fraumeni-like family with cardiac angiosarcoma (PMID: 36387164).
• Xeroderma pigmentosum: Patients with XP have elevated skin cancer risk including angiosarcoma, due to defective nucleotide excision repair (PMID: 39221877).

Environmental Risk Factors

Demographic Risk Factors

• Age: Median age at diagnosis is 69 years (range 0–102) (PMID: 35478727)
• Sex: Male predominance overall; male:female ratio approximately 3:1 for hepatic AS
• Race/Ethnicity: Predominantly non-Hispanic Caucasian (75.4% in SEER data)

Protective Factors

No well-established genetic or environmental protective factors have been identified for angiosarcoma. Avoidance of known carcinogens (vinyl chloride, arsenic, excessive UV) reduces risk for specific subtypes. Female sex has been identified as a positive prognostic factor for hepatic angiosarcoma (HR 0.68, 95% CI 0.536–0.875, P < 0.05) (PMID: 39676119).

Gene-Environment Interactions

The interaction between germline TP53 variants and ionizing radiation represents the best-characterized gene-environment interaction in angiosarcoma. Patients with Li-Fraumeni syndrome who receive radiotherapy have significantly elevated risk of developing secondary angiosarcoma, as radiation-induced DNA damage overwhelms already-compromised DNA damage response pathways. Similarly, xeroderma pigmentosum patients exposed to UV radiation develop cutaneous angiosarcoma at increased rates due to defective nucleotide excision repair.

3. Phenotypes

Clinical Presentations by Site

Cutaneous Angiosarcoma (Head and Neck)

• Phenotype type: Physical manifestation — raised, violaceous or erythematous plaques/nodules on sun-exposed skin
• HPO terms: HP:0100242 (Sarcoma), HP:0000951 (Abnormality of the skin)
• Age of onset: Typically elderly (median ~70 years)
• Severity: Severe — aggressive local invasion with multifocal disease
• Progression: Rapidly progressive
• Frequency: Most common subtype of cutaneous angiosarcoma
• QoL impact: Severe — disfiguring facial lesions cause significant psychological distress

Breast Angiosarcoma

• Phenotype type: Physical manifestation — mass or skin changes in breast
• HPO terms: HP:0100242 (Sarcoma), HP:0100013 (Neoplasm of the breast)
• Onset: Primary: median age 31 years; Radiation-associated: median age 68–72 years; latency 4–12 years post-RT (PMID: 19433291)
• Severity: Variable — graded by Rosen's method (low, intermediate, high)
• Frequency: 0.1–0.2% of malignant breast neoplasms

Cardiac Angiosarcoma

• Phenotype type: Clinical signs — pericardial effusion, cardiac tamponade, dyspnea
• HPO terms: HP:0001698 (Pericardial effusion), HP:0002094 (Dyspnea)
• Location: Predominantly right atrium
• Severity: Severe — most aggressive primary cardiac malignancy
• Clinical features: Hemorrhagic pericardial effusion, cardiac tamponade (PMID: 41320327)

Hepatic Angiosarcoma

• Phenotype type: Clinical signs — abdominal pain, hepatomegaly, hepatic rupture
• HPO terms: HP:0001392 (Abnormality of the liver), HP:0002027 (Abdominal pain)
• Severity: Extremely poor prognosis — 3-year survival rate 6.7% (PMID: 39676119)

Splenic Angiosarcoma

• Phenotype type: Clinical signs — acute abdominal pain, splenic rupture, hemoperitoneum
• HPO terms: HP:0001743 (Abnormality of the spleen), HP:0002027 (Abdominal pain)
• Severity: Nearly universally fatal — most patients die within 12 months

Pulmonary Metastatic Disease

• Phenotype type: Symptoms — hemoptysis (73% of patients), dyspnea
• HPO terms: HP:0002105 (Hemoptysis), HP:0002094 (Dyspnea)
• Imaging: Bilateral, randomly distributed, variably shaped nodules with ground-glass opacities
• Common misdiagnoses: Tuberculosis (45%), vasculitis (18%) (PMID: 28885371)

Laboratory Abnormalities

• Anemia (from hemorrhage or microangiopathic hemolytic process)
• Thrombocytopenia (consumptive coagulopathy / Kasabach-Merritt phenomenon)
• Elevated LDH

4. Genetic/Molecular Information

Somatic Driver Genes and Pathogenic Variants

Primary/Sporadic Angiosarcoma

Source: PMID: 32123305 — "Recurrent genomic alterations were identified in KDR (70%), PIK3CA/PIK3R1 (70%), and PTPRB (30%), each at higher frequencies than reported in AS across all sites. Six tumors harbored a KDR p.T771R hotspot mutation, and all seven KDR-mutant cases showed evidence suggestive of biallelism."

Head and Neck (UV-Associated) Angiosarcoma

UV-positive cases had significantly higher TMB than UV-negative cases (P = 0.0294) (PMID: 37106027).

Radiation-Associated Angiosarcoma

Source: PMID: 20949568 — "High-level MYC amplification was found in 100% of secondary AS, but in none of the AVL or other radiation-associated sarcomas. Coamplification of FLT4 (encoding VEGFR3) was identified in 25% of secondary AS."

PMID: 25863565 — "Amplification (5- to 20-fold) of the c-myc oncogene was found in all breast radiation-induced angiosarcomas (32 tumours) but in none of the 15 primary angiosarcomas except one (7%). This study reinforces that there are true pathogenetic differences between the two types of breast angiosarcomas."

Hepatic Angiosarcoma

• K-ras-2 point mutations found in 29% of tumors (7/24), including both sporadic (26%) and Thorotrast-induced (40%) cases. Mutations were characteristic of oxidative damage (G:C > A:T and G:C > T:A) (PMID: 9010458).
• Aristolochic acid signature (SBS22) identified in 80% of Asian liver angiosarcoma cases (PMID: 41394772).

Epigenetic Information

• Radiation-associated angiosarcomas show a distinct transcriptome signature featuring upregulation of lymphatic endothelial markers (PDPN, PROX-1, VEGFR3, EDNRA), suggesting origin from radiation-stimulated lymphatic endothelial cells (PMID: 22532251).
• MYC amplification drives upregulation of the miR-17-92 cluster with concomitant downregulation of thrombospondin-1 (THBS1), linking MYC to angiogenic promotion (PMID: 22383169).
• Alternative lengthening of telomeres (ALT) activation has been identified as a hallmark of liver angiosarcoma (PMID: 41394772).

Chromosomal Abnormalities

• MYC amplification at 8q24.21 (5- to 20-fold) — hallmark of radiation-associated AS
• CDKN2A/CDKN2B losses at 9p21.3 — more frequent in radiation-associated (71%) than sporadic (39%) sarcomas (P = 6.92e-3) (PMID: 31243333)
• Gains of 17q24.2-17qter identified in subsets of post-radiation angiosarcomas
• Rare ALK rearrangements reported in epithelioid angiosarcoma (PMID: 41836264)

5. Environmental Information

Environmental Factors

• CHEBI terms: Vinyl chloride (CHEBI:28509), Arsenic (CHEBI:22632), Aristolochic acid (CHEBI:22574)

Lifestyle Factors

No specific lifestyle factors (smoking, diet, exercise, alcohol) have been definitively linked to angiosarcoma risk beyond the occupational and environmental exposures listed above. Androgenic-anabolic steroid use has been associated with hepatic angiosarcoma in rare cases (PMID: 7199426).

Infectious Agents

Viral hepatitis (HBV, HCV) has been investigated but not confirmed as a major risk factor for hepatic angiosarcoma. In a Taiwanese study, 2 of 9 patients had hepatitis C infection and none had hepatitis B, with no evidence supporting a major viral role (PMID: 22200164).

6. Mechanism / Pathophysiology

Molecular Pathways

Angiosarcoma pathogenesis involves convergent activation of several key signaling cascades:

VEGF/VEGFR Signaling (Primary Pathway) - KDR (VEGFR2) activating mutations drive autocrine/paracrine VEGF signaling - FLT4 (VEGFR3) amplification in radiation-associated AS enhances lymphangiogenic signaling - VEGF stimulates tumor proliferation via VEGFR2 phosphorylation (PMID: 23522954)

PI3K-AKT-mTOR Pathway - PIK3CA activating mutations (H1047R hotspot) found in both human AS and canine HSA - mTOR/S6K activation demonstrated in vascular tumors including angiosarcoma; rapamycin inhibits growth (PMID: 23938603) - Combined MEK + mTOR inhibition shows synergistic anti-tumor effects in AS tumorgrafts (PMID: 25955301)

RAS-MAPK Pathway - NRAS activating mutations (G61R) in 24% of canine HSA - K-ras-2 mutations in hepatic AS (29%), characteristic of oxidative damage - MEK inhibitor sensitivity demonstrated in AS tumorgraft models

MYC Signaling (Radiation-Associated) - MYC amplification → upregulation of miR-17-92 cluster → suppression of THBS1 → enhanced angiogenesis (PMID: 22383169) - MYC also drives cell cycle progression and metabolic reprogramming

Wnt/β-Catenin Pathway - SFRP2 overexpression activates calcineurin/NFATc3 pathway and β-catenin signaling - Anti-SFRP2 monoclonal antibody reduced angiosarcoma tumor volume by 58% (P = 0.004) (PMID: 23604067)

Tie2/Angiopoietin Pathway - Tie2 universally expressed in human angiosarcomas - Tie2 antagonism combined with VEGFR inhibition shows synergistic anti-tumor effects (PMID: 22431921)

Causal Chain: From Trigger to Clinical Manifestation

Environmental trigger (radiation/UV/chemical)
    OR
Sporadic somatic mutations
│
▼
Endothelial cell DNA damage / Oncogenic activation
(MYC amplification | KDR/PIK3CA mutations | K-ras mutations)
│
▼
Constitutive activation of:
  - VEGF/VEGFR signaling → proliferation
  - PI3K/AKT/mTOR → survival, metabolism
  - RAS/MAPK → growth, differentiation
  - MYC → cell cycle, angiogenesis (via miR-17-92/THBS1)
│
▼
Loss of cell cycle control (CDKN2A/p53 loss)
│
▼
Uncontrolled endothelial proliferation
Aberrant vascular channel formation
│
▼
Local invasion, hemorrhage, distant metastasis

Cellular Processes

• Angiogenesis (GO:0001525) — central to tumor biology; tumor cells form dysfunctional vascular channels
• Cell proliferation (GO:0008283) — driven by VEGFR, PI3K, and MAPK signaling
• Apoptosis resistance (GO:0006915) — ROCK knockdown enhances survival through reduced caspase cleavage (PMID: 22934846)
• Cell migration (GO:0016477) — essential for invasion and metastasis
• Inflammation — gene expression profiling identifies inflammation as a distinguishing feature (PMID: 21062482)

Cell Types Involved

• Vascular endothelial cells (CL:0000071) — cell of origin
• Lymphatic endothelial cells (CL:0002138) — particularly in radiation-associated AS
• Tumor-infiltrating T cells (CL:0000084) — CD3+, CD4+, CD8+ cells correlate with immunotherapy response
• Tumor-associated macrophages — contribute to immunosuppressive microenvironment

Immune System Involvement

The tumor microenvironment of angiosarcoma is characterized by: - Variable immune infiltration — higher TIL density correlates with better immunotherapy response - PD-L1 expression in 32% of post-radiation breast AS specimens (PMID: 41693531) - Upregulation of immune checkpoints (CTLA4, LAG3, PD-1, CD86) in tumor-infiltrating immune cells (PMID: 40575034) - CXCL12-CXCR4 axis as a crucial mediator of the TME (PMID: 40474296) - Lower immune infiltrate at tumor periphery associated with more aggressive behavior (PMID: 31243333)

Single-Cell and Spatial Transcriptomics Findings

Single-cell RNA sequencing of breast angiosarcoma revealed significant differences in perivascular cells, fibroblasts, T cells, endothelial cells, and myeloid cells compared to invasive breast cancer. Key genes FAT4, KDR, FN1, and KIT were highly expressed in angiosarcoma endothelial cells, correlating with poor prognosis (PMID: 40474296).

Spatial transcriptomics of head and neck angiosarcoma revealed topological immune landscapes with distinct spatial organization of immune cell populations (PMID: 37106027).

Single-cell transcriptomic analysis of pancreatic angiosarcoma liver metastasis demonstrated marked upregulation of NF-κB, HIF-1, and MYC signaling, with an immunosuppressive and angiogenic tumor ecosystem (PMID: 40575034).

7. Anatomical Structures Affected

Organ Level

Primary Sites:

Common Metastatic Sites: - Lung (most common) — UBERON:0002048 - Liver — UBERON:0002107 - Bone — UBERON:0001474 - Lymph nodes — UBERON:0000029 - Brain — UBERON:0000955

Tissue and Cell Level

• Vascular endothelium (UBERON:0001986) — tissue of origin
• Lymphatic endothelium — particularly in radiation-associated subtypes
• Cell populations: Endothelial cells (CL:0000071), pericytes (CL:0000669)

Subcellular Level

• Cell membrane (GO:0005886) — VEGFR2, Tie2 receptor signaling
• Nucleus (GO:0005634) — MYC transcription factor activity, TP53 function
• Cytoplasm (GO:0005737) — PI3K/AKT/mTOR signaling cascade

8. Temporal Development

Onset

• Primary angiosarcoma: Typically adult-onset, median age 69 years; primary breast AS median age 31 years
• Radiation-associated AS: Median latency 9.1 years (range 3.7–46.3) from index radiation
• Chemically-induced hepatic AS: Latency 20–40+ years from exposure onset
• Onset pattern: Insidious — often misdiagnosed due to nonspecific presentation

Progression

Staging: The AJCC staging system for soft tissue sarcomas applies. At presentation, tumors are frequently high grade (Grade III 17.2%, Grade IV 19%, unknown 50.6%) but half are considered localized (PMID: 35478727).

Progression Rate: Rapidly progressive — median PFS 7 months, median OS 20 months across all subtypes (PMID: 40500777).

Disease Course: Aggressive, progressive course with high rates of local recurrence and distant metastasis. 12 of 36 patients (33%) developed local recurrence and 12 developed metastasis in one head/neck AS series (PMID: 38391320).

Critical Periods

Early diagnosis and complete surgical resection represent the critical window for optimal outcomes. Once metastatic disease develops, prognosis is uniformly poor. The median OS for patients with pulmonary metastases was only 5.0 months (PMID: 28885371).

9. Inheritance and Population

Epidemiology

• Incidence: Age-adjusted incidence rate approximately 1.4 per million per year (PMID: 35478727)
• Prevalence: Extremely rare — <1–2% of all soft tissue sarcomas
• SEER data: 5,135 patients identified between 1975 and 2016

Inheritance Patterns

Angiosarcoma is predominantly a sporadic cancer without Mendelian inheritance. However: - Li-Fraumeni syndrome (autosomal dominant TP53 mutations) — increased risk, especially with radiation exposure - Xeroderma pigmentosum (autosomal recessive) — increased risk of UV-associated AS - Familial cases: Rare; a CHEK2 p.P35L variant was identified in a family with cardiac angiosarcoma (PMID: 36387164)

Population Demographics

• Sex ratio: Overall slight male predominance (46% male in SEER); hepatic AS has strong male predominance (~3:1); breast AS almost exclusively female
• Race/Ethnicity: Non-Hispanic Caucasian 75.4%; Non-Hispanic Asians/Pacific Islanders overrepresented in hepatic AS (17%) (PMID: 39676119)
• Age distribution: Predominantly elderly; median age 69 years overall; younger for primary breast AS (median 31)
• Geographic variation: Higher liver AS incidence in Asia (aristolochic acid exposure); historically elevated in industrial areas with vinyl chloride exposure

10. Diagnostics

Histopathology and Immunohistochemistry

Histological diagnosis relies on identification of malignant endothelial cells forming abnormal vascular channels. Morphologic spectrum ranges from well-differentiated vasoformative patterns to poorly differentiated solid sheets of epithelioid or spindle cells.

Essential IHC Panel:

MYC IHC: c-MYC immunostain is consistently positive in radiation-associated AS and negative/weakly positive in primary AS — serves as a diagnostic marker for distinguishing these subtypes (PMID: 34392127, PMID: 24457083).

MYC FISH: Confirms MYC amplification with 100% concordance with protein expression in mammary AS (PMID: 24457083).

Imaging Studies

• MRI: Preferred for soft tissue characterization; hemorrhagic, heterogeneously enhancing masses
• CT: Assessment of extent and metastatic disease
• PET-CT: Useful for staging and response assessment
• Cardiac MRI: Superior to echocardiography for detecting cardiac masses (PMID: 28885371)

Molecular/Genetic Testing

• Targeted NGS panels: Identify actionable mutations in KDR, PIK3CA, TP53, NRAS
• MYC FISH: Diagnostic for radiation-associated vs primary AS
• TMB assessment: Predictive of immunotherapy response in UV/radiation-associated subtypes
• Whole-exome sequencing: For comprehensive genomic profiling and germline testing

Differential Diagnosis

11. Outcome/Prognosis

Survival and Mortality

Prognostic Factors

Negative prognostic factors (multivariate): - Age > 70 years (HR 1.67, P < 0.05) - No surgical intervention (HR 2.29, P < 0.001) - Distant stage (HR 2.54, P < 0.001) - Angiosarcoma histology (HR 2.95 for local relapse in superficial sarcomas, P < 0.001) (PMID: 40961809) - Higher tumor grade - Larger tumor size - Non-cutaneous location

Positive prognostic factors: - Female sex (HR 0.68 for hepatic AS) - Localized disease - Complete surgical resection with R0 margins - Younger age

Complications

• Hemorrhage (tumor rupture, especially splenic and hepatic)
• Disseminated intravascular coagulation
• Cardiac tamponade (cardiac AS)
• Treatment-related thrombotic microangiopathy (PMID: 41177756)

12. Treatment

Surgical Treatment

Wide surgical excision is the mainstay of treatment for localized angiosarcoma. In SEER data, 66.1% of patients underwent surgery (PMID: 35478727). Complete resection with negative margins (R0) is critical — patients without R0 margins had significantly worse outcomes (HR 2.60 for LRFS, P < 0.001; HR 2.02 for OS, P < 0.001) (PMID: 40961809).

• MAXO terms: MAXO:0000004 (surgical procedure), MAXO:0000015 (mastectomy)

Chemotherapy

First-line agents: - Paclitaxel — anti-angiogenic and cytotoxic; widely used for cutaneous AS - Doxorubicin/liposomal doxorubicin — standard for soft tissue sarcomas - Gemcitabine ± docetaxel — alternative regimen

Neoadjuvant chemotherapy: Applied to improve R0 resection rates; response evenly divided between poor (Grades I–II) and good responders (Grades III–IV) (PMID: 38722225).

• MAXO terms: MAXO:0000058 (chemotherapy)

Immunotherapy

Immune checkpoint inhibitors represent an emerging treatment paradigm, particularly for UV- and radiation-associated subtypes:

Cemiplimab (anti-PD-1): Phase II CEMangio trial in secondary AS — ORR 27.8% (4 PR, 1 CR), median PFS 3.7 months, median OS 13.1 months. High intratumoral CD3+ (P = 0.019), CD4 (P = 0.046), and CD8+ density associated with response (PMID: 40632032).

Cabozantinib + nivolumab: Alliance A091902 second-line — ORR 59%, demonstrating significant efficacy in both cutaneous and non-cutaneous AS (PMID: 40056281).

Dual ICI (SWOG S1609): ORR 25% — suggests potential benefit but limited activity in cutaneous disease (PMID: 40056281).

Pembrolizumab: Sustained response reported in PD-L1-expressing angiosarcoma; one patient achieved marked liver disease shrinkage with no new lesions for 8+ months off therapy (PMID: 28716069).

• MAXO terms: MAXO:0001360 (immune checkpoint inhibitor therapy)

Targeted Therapy

• Anti-VEGF/VEGFR agents: Bevacizumab, pazopanib, sorafenib, sunitinib — variable efficacy; sunitinib showed limited activity against AS in preclinical models (PMID: 23522954)
• mTOR inhibitors: Rapamycin shows synergy with MEK inhibitors in AS (PMID: 25955301)
• Anti-SFRP2 antibody: Reduced AS tumorgraft volume by 58% (P = 0.004) (PMID: 23604067)
• CDK4/6 inhibitors: Suggested by frequent cell cycle dysregulation (PMID: 41246336)
• Anlotinib, lenvatinib: Multi-kinase inhibitors used in refractory disease

Radiation Therapy

Adjuvant radiation therapy is used for local control, particularly for head/neck cutaneous AS. However, radiation is used cautiously for radiation-associated subtypes.

• MAXO terms: MAXO:0000014 (radiation therapy)

Experimental Treatments

• Photodynamic therapy (PDT): Promising for recurrent superficial cutaneous AS (PMID: 40364848)
• IFN-alpha: Inhibited angiosarcoma growth in murine models by 71–79% through angiogenesis inhibition (PMID: 16689662)
• Anti-extracellular vimentin vaccine (iBoost): In canine HSA, median OS increased from 136 to 235 days when combined with doxorubicin (PMID: 41009669)
• Toripalimab + gemcitabine/nab-paclitaxel: Achieved 9-month partial response in radiation-associated laryngeal AS (PMID: 41496010)

13. Prevention

Primary Prevention

• Occupational safety: Elimination of vinyl chloride exposure through engineering controls and regulatory limits — largely achieved in developed countries
• Arsenic exposure reduction: Clean water initiatives in endemic areas
• UV protection: Sun-protective measures for head/neck AS prevention
• Judicious use of radiotherapy: Appropriate patient selection and field design

Secondary Prevention

• Surveillance after breast radiation: Clinical monitoring for skin changes in irradiated fields, given 3-fold increased incidence of secondary breast AS. Hemangiosarcoma SIR was 27.11 (95% CI 21.6–33.61) on breast/trunk skin after breast radiation (PMID: 38457179)
• Monitoring chronic lymphedema patients: Regular examination for Stewart-Treves syndrome
• Germline TP53 testing: In patients with early-onset or radiation-associated AS, to identify Li-Fraumeni syndrome for cancer surveillance in families

Tertiary Prevention

• Close surveillance for local recurrence and metastatic disease after treatment
• Multidisciplinary follow-up with sarcoma specialists
• Prompt treatment of recurrences

14. Other Species / Natural Disease

Canine Hemangiosarcoma

Canine hemangiosarcoma (HSA) is the most important comparative model for human angiosarcoma. It is a common spontaneous malignancy in dogs, particularly in golden retrievers, German shepherds, and Labrador retrievers.

Taxonomy: Canis lupus familiaris (NCBI Taxon: 9615)

Genomic Similarities: Whole-exome sequencing of 47 golden retriever HSAs revealed striking parallels with human angiosarcoma: - PIK3CA mutations: 46% (vs. 70% in human primary mammary AS) - TP53 mutations: 66% - NRAS mutations: 24% (G61R hotspot) - PLCG1 mutations: 4% - PTEN mutations: 6%

"Overall, we identified potential driver mutations in over 90% of the cases, including well-documented (in human cancers) oncogenic mutations in PIK3CA (46%), PTEN (6%), PLCG1(4%), and TP53 (66%), as well as previously undetected recurrent activating mutations in NRAS (24%)" (PMID: 32210430).

"Canine tumors share mutational hotspots with human tumors in oncogenes including PIK3CA, KRAS, NRAS, BRAF, KIT and EGFR. Hotspot mutations with significant association to tumor type include NRAS G61R and PIK3CA H1047R in hemangiosarcoma" (PMID: 37414794).

Clinical Features: Splenic HSA is the most common form, characterized by rapid growth, splenic rupture, and hemoperitoneum. Median survival after splenectomy alone is 1–3 months; with adjuvant doxorubicin, 5–7 months (PMID: 41009669). Stage III disease and hepatic metastases are associated with significantly decreased survival (P < 0.001) (PMID: 41742582).

Gene expression profiling identified inflammation and angiogenesis as distinguishing features of canine HSA compared to non-malignant endothelial cells (PMID: 21062482).

Other Species

Angiosarcoma/hemangiosarcoma is recognized in multiple mammalian species but is particularly prevalent in dogs. The shared mutational landscape and biological behavior make canine HSA an invaluable One Health model for drug development.

15. Model Organisms

In Vivo Models

Canine Hemangiosarcoma (Spontaneous) - Model type: Large animal, spontaneous - Phenotype recapitulation: Excellent — shared driver mutations, aggressive behavior, vascular origin, metastatic patterns - Applications: Drug development, immunotherapy testing, biomarker discovery - Limitations: Heterogeneous genetic background; breed-specific predispositions may not fully reflect human disease - Key cell isolates: Used for tumorgraft models and in vitro drug screening

Murine Models - SVR cell line: Transformed murine endothelial cells expressing oncogenic H-ras; forms angiosarcomas in nude mice (PMID: 16689662) - MS1-VEGF cell line: Murine endothelial cells expressing VEGF; low-grade angiosarcoma model - HAMON xenograft: Human angiosarcoma cell line xenograft in immunodeficient mice; expresses CD31, VEGFR2 (PMID: 23522954) - Applications: Drug testing (MEK/mTOR inhibitors, anti-angiogenic agents, immunotherapy)

In Vitro Models

• Human angiosarcoma cell lines (limited availability)
• Canine HSA cell isolates — used for drug combination studies
• Patient-derived xenografts (PDX) / tumorgrafts

Model Limitations

• Murine xenograft models lack intact immune system
• Cell line models may not capture tumor heterogeneity
• Canine HSA, while closely related, is not identical to human AS (e.g., MYC amplification is not a feature of canine HSA)
• Limited availability of human AS cell lines due to disease rarity

Key Findings — Detailed Evidence

Finding 1: Angiosarcoma is a Rare, Aggressive Vascular Malignancy with Poor Prognosis

Analysis of 5,135 patients in the SEER database (1975–2016) demonstrated an age-adjusted incidence rate of approximately 1.4 per million, with the majority of patients presenting as non-Hispanic Caucasian (75.4%) with a median age of 69 years. Tumor grades were predominantly high at presentation (Grade III 17.2%, Grade IV 19%), and the overall 5-year survival was 26.7% (95% CI 25.4–28.1%). A single-institution cohort of 128 patients confirmed poor outcomes with median PFS of 7 months and median OS of 20 months. Importantly, non-cutaneous angiosarcoma had significantly worse median OS than cutaneous disease (9 vs 36 months, P = 0.04), highlighting the prognostic importance of anatomic site.

Finding 2: MYC Amplification Defines Radiation-Associated Angiosarcoma

MYC amplification at 8q24 (5- to 20-fold) is present in 100% of radiation-associated breast angiosarcomas but in only 0–7% of primary angiosarcomas, establishing it as both a diagnostic biomarker and a mechanistic driver. FLT4 (VEGFR3) coamplification occurs in 25% of secondary AS. Downstream, MYC amplification drives upregulation of the miR-17-92 cluster and suppression of the anti-angiogenic factor thrombospondin-1, providing a mechanistic link between MYC and the angiogenic phenotype.

Finding 3: Primary Angiosarcoma Has Distinct Angiogenic Driver Mutations

Primary mammary angiosarcomas harbor recurrent activating mutations in KDR (70%), PIK3CA/PIK3R1 (70%), and PTPRB (30%), all at higher frequencies than in angiosarcoma across all sites. The KDR T771R hotspot mutation shows evidence of biallelism, indicating strong selection for constitutive VEGFR2 activation. Head/neck UV-associated angiosarcomas have a distinct mutational profile dominated by CSMD3, LRP1B, MUC16, POT1, and TP53 mutations with high TMB.

Finding 4: Canine Hemangiosarcoma as a Comparative Model

Canine hemangiosarcoma shares driver mutations in PIK3CA (46%), TP53 (66%), and NRAS (24%) with human angiosarcoma, with identical hotspot mutations (PIK3CA H1047R, NRAS G61R). This genomic convergence, combined with similar clinical behavior, validates canine HSA as a One Health model for therapeutic development.

Finding 5: Immunotherapy Shows Emerging Activity

Immune checkpoint inhibitors demonstrate meaningful activity in angiosarcoma, particularly in UV- and radiation-associated subtypes. The CEMangio phase II trial showed an ORR of 27.8% with cemiplimab in secondary AS, with high intratumoral CD3+ and CD8+ density predicting response. The cabozantinib-nivolumab combination achieved a remarkable 59% ORR in second-line, suggesting synergy between anti-angiogenic and immune checkpoint blockade.

Finding 6: Environmental Carcinogens Cause Distinct Subtypes

Vinyl chloride, thorotrast, arsenic, ionizing radiation, and UV radiation each cause distinct angiosarcoma subtypes through different mutagenic mechanisms — from oxidative DNA damage (K-ras mutations in hepatic AS) to DNA adduct formation (aristolochic acid SBS22 signature) to direct chromosomal amplification events (MYC in radiation-associated AS).

Mechanistic Model: Integrated Pathogenesis of Angiosarcoma Subtypes

┌─────────────────────────────────────────────────────────────────┐
│                    ANGIOSARCOMA SUBTYPES                        │
├─────────────┬──────────────┬────────────┬──────────┬────────────┤
│  Primary/   │  Radiation-  │ UV-Head/   │ Chemical │ Lymphedema │
│  Sporadic   │  Associated  │   Neck     │ Hepatic  │ (Stewart-  │
│             │              │            │          │  Treves)   │
├─────────────┼──────────────┼────────────┼──────────┼────────────┤
│ KDR (70%)   │ MYC amp      │ UV sig     │ K-ras    │ Unknown    │
│ PIK3CA(70%) │ (100%)       │ (SBS7)     │ (29%)    │ drivers    │
│ PTPRB (30%) │ FLT4 (25%)   │ High TMB   │ SBS22    │            │
│             │ CDKN2A loss  │ CSMD3,POT1 │ (AA)     │            │
├─────────────┼──────────────┼────────────┼──────────┼────────────┤
│             │              │            │          │            │
│   VEGFR2 ←──→  MYC/miR ←──→  DNA       │  Oxid.  │ Chronic    │
│   PI3K/AKT  │  17-92      │  repair    │  damage  │ inflam.    │
│   mTOR      │  THBS1↓     │  defects   │          │            │
├─────────────┴──────────────┴────────────┴──────────┴────────────┤
│            CONVERGENT DOWNSTREAM PATHWAYS                       │
│  ┌─────────────────────────────────────────────────────┐       │
│  │ Angiogenesis ↑ │ Cell cycle ↑ │ Apoptosis ↓        │       │
│  │ VEGF/VEGFR    │ CDKN2A loss  │ TP53 loss           │       │
│  │ Tie2/Ang      │ MYC          │ PI3K/AKT            │       │
│  └─────────────────────────────────────────────────────┘       │
│                          ↓                                      │
│           Malignant Endothelial Proliferation                   │
│           Aberrant Vascular Channel Formation                   │
│           Local Invasion → Hemorrhage → Metastasis              │
└─────────────────────────────────────────────────────────────────┘

Evidence Base

Landmark Papers

Limitations and Knowledge Gaps

1. Rarity precludes large randomized trials: Most treatment evidence comes from retrospective series, small phase II trials, and case reports. No phase III randomized trials exist for any angiosarcoma treatment.

2. Molecular heterogeneity: The marked molecular diversity across subtypes makes unified treatment approaches challenging. Better subtype-specific trial designs are needed.

3. Limited understanding of primary sporadic AS pathogenesis: While radiation-associated and chemical subtypes have clear initiating events, the triggers for primary sporadic AS remain largely unknown.

4. Biomarker validation: Predictive biomarkers for immunotherapy response (TMB, PD-L1, TIL density) require prospective validation in larger cohorts.

5. Incomplete genomic landscape: Whole-genome sequencing has been performed on limited cohorts; non-coding mutations, structural variants, and epigenomic alterations remain underexplored.

6. Lack of standardized staging: The AJCC staging system for soft tissue sarcomas may not adequately capture the prognostic nuances of angiosarcoma across different anatomic sites.

7. Limited cell line resources: Few authenticated human angiosarcoma cell lines exist, hampering preclinical drug development.

8. Underrepresentation of non-Western populations: Most genomic and clinical data derive from Western populations; the role of aristolochic acid in Asian liver AS is only now being characterized.

Proposed Follow-up Experiments/Actions

1. Prospective biomarker-stratified clinical trials: Design trials stratifying patients by molecular subtype (MYC-amplified, KDR-mutant, high-TMB) to match targeted therapies to specific driver alterations.

2. Combinatorial immunotherapy-TKI trials: Given the 59% ORR with cabozantinib-nivolumab, expand this approach with additional anti-angiogenic/ICI combinations across subtypes.

3. Comprehensive genomic profiling: Perform whole-genome sequencing on a large, multi-institutional angiosarcoma cohort to identify non-coding drivers, structural variants, and novel therapeutic targets.

4. Canine comparative trials: Leverage canine HSA as a platform for rapid therapeutic testing — particularly for PIK3CA inhibitors, NRAS-targeted approaches, and immunotherapy combinations.

5. Single-cell multi-omics: Expand scRNA-seq studies to characterize the tumor microenvironment across subtypes, with focus on identifying determinants of immunotherapy response.

6. Liquid biopsy development: Develop ctDNA assays for MYC amplification, KDR mutations, and other actionable alterations to enable non-invasive diagnosis and monitoring.

7. CDK4/6 inhibitor trials: Given frequent CDKN2A loss across subtypes, test CDK4/6 inhibitors (palbociclib, ribociclib) as single agents and in combinations.

8. MEK + mTOR combination trials: Translate preclinical synergy data into clinical trials for patients with RAS/MAPK pathway-activated angiosarcomas.

9. Epidemiological surveillance: Monitor aristolochic acid-associated liver angiosarcoma in Asian populations and implement public health interventions.

10. Patient-partnered research: Expand the Angiosarcoma Project (ASCProject) to increase patient enrollment, diversity, and longitudinal follow-up for this rare disease.

Report generated: 2026-05-05 Sources: SEER database analyses, genomic profiling studies, clinical trials, systematic reviews, and comparative oncology studies spanning 93 reviewed publications.